Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Has Average Price Target of $45.54

Key Points

• Analyst sentiment is broadly positive: Tango has a “Moderate Buy” consensus, with 13 of 17 analysts rating it Buy and an average 12-month price target of $45.54. The stock was cited at $24.30.
• Tango reported a quarterly loss of $0.39 per share, missing the $0.35-per-share loss analysts expected. Wedbush and HC Wainwright lowered their price targets, though both maintained positive ratings.
• The company reported promising results from a pancreatic cancer combination study, including an 82% objective response rate, and said it expects to begin a registrational Phase 3 trial in the first half of 2027. It also reported $977.5 million in cash as of September 30.

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seventeen analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $45.54.

Several brokerages have recently weighed in on TNGX. William Blair assumed coverage on shares of Tango Therapeutics in a research report on Friday, October 16th. They set an "outperform" rating on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Tango Therapeutics in a research report on Wednesday, November 4th. HC Wainwright dropped their price target on shares of Tango Therapeutics from $68.00 to $67.00 and set a "buy" rating for the company in a research report on Tuesday. Wedbush cut their price target on shares of Tango Therapeutics from $45.00 to $40.00 and set an "outperform" rating for the company in a research note on Tuesday. Finally, Zacks Research downgraded Tango Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 27th.

Insider Buying and Selling

In related news, insider Jessica Newcomb sold 8,200 shares of the business's stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $24.22, for a total value of $198,604.00. Following the sale, the insider owned 59,121 shares of the company's stock, valued at $1,431,910.62. The trade was a 12.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Adam Crystal sold 27,000 shares of the business's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $24.47, for a total value of $660,690.00. Following the completion of the sale, the insider directly owned 115,743 shares in the company, valued at approximately $2,832,231.21. This represents a 18.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 47,231 shares of company stock valued at $1,129,029. 6.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TNGX. Nykredit A S acquired a new stake in shares of Tango Therapeutics in the 2nd quarter valued at $26,000. Allworth Financial LP bought a new stake in shares of Tango Therapeutics in the 2nd quarter worth about $35,000. Global Retirement Partners LLC bought a new stake in shares of Tango Therapeutics in the 2nd quarter worth about $122,000. Sterling Capital Management LLC increased its position in shares of Tango Therapeutics by 838.8% during the 3rd quarter. Sterling Capital Management LLC now owns 4,647 shares of the company's stock worth $116,000 after purchasing an additional 4,152 shares in the last quarter. Finally, ACT Capital Partners L.P. acquired a new stake in shares of Tango Therapeutics during the 3rd quarter worth about $150,000. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Tango Therapeutics Price Performance

TNGX opened at $24.30 on Wednesday. The company has a market capitalization of $4.10 billion, a P/E ratio of -17.74 and a beta of 1.26. The firm's fifty day moving average price is $23.35 and its two-hundred day moving average price is $22.59. Tango Therapeutics has a fifty-two week low of $7.49 and a fifty-two week high of $34.39.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). On average, equities research analysts expect that Tango Therapeutics will post -1.41 EPS for the current fiscal year.

Trending Headlines about Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: A Phase 1/2 combination study of vopimetostat and daraxonrasib in second- and third-line pancreatic cancer reported an 82% objective response rate and 88% nine-month progression-free survival, with the regimen generally well tolerated. Tango expects to start a registrational Phase 3 trial in front-line MTAP-deleted pancreatic cancer in the first half of 2027. The company also reported $977.5 million in cash as of September 30. Tango Therapeutics Q3 2026 results and business highlights
• Positive Sentiment: JPMorgan raised its price target to $47 from $46 and maintained an Overweight rating, signaling continued optimism about TNGX’s prospects. JPMorgan analyst recommendations
• Neutral Sentiment: A report listed short interest at zero shares and a zero days-to-cover ratio. This unusually low reported figure offers little clear indication of investor positioning.
• Negative Sentiment: Tango reported a third-quarter loss of $0.39 per share, missing the analyst consensus estimate of a $0.35 loss by $0.04. Tango Therapeutics quarterly earnings press release
• Negative Sentiment: Wedbush cut its target to $40 from $45, while retaining an Outperform rating; HC Wainwright lowered its target to $67 from $68 but kept a Buy rating. The reductions temper the bullish analyst outlook, although both targets remain above the stock’s cited $24.30 price. Wedbush analyst recommendations HC Wainwright analyst recommendations

About Tango Therapeutics

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.